

Applicant : Alan R. Tall  
Serial No.: 09/560,372  
Filed : April 28, 2000  
Page 8

#### REMARKS

Claims 1, 2, 5-16, 18-25, 50 and 51 were pending in the subject application. Applicant herein above has amended claims 1, 15 and 50. Accordingly, claims 1, 2, 5-16, 18-25, 50 and 51 are presented for the Examiner's consideration.

Support for the amendment to claims 1 and 50 is discussed below in applicant's reply to the rejection under 35 U.S.C. § 112, second paragraph.

#### Objection to Specification

On page 2 of the August 28, 2003 Office Action, the Examiner objected to the presence of hyperlinks in the specification.

In response, applicant has amended the specification to not contain anything resembling a link, but to instead provide the proper citation to documents obtained in the Internet. Accordingly, applicant respectfully requests that the Examiner reconsider and withdraw this objection.

#### Rejection under 35 U.S.C. § 112, first paragraph Enablement

On pages 2-4 of the August 28, 2003 Office Action, the Examiner rejected claims 15-25 under 35 U.S.C. § 112, first paragraph, alleging that the specification, while being enabling for method of expressing foreign DNA in a host cell *in vitro*, does not reasonably provide enablement for methods of expressing foreign DNA in a host cell *in vivo*. The Examiner alleged that the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. The Examiner noted that the aspects of the previous enablement rejection directed to methods of transforming a host

Applicant : Alan R. Tall  
Serial No.: 09/560,372  
Filed : April 28, 2000  
Page 9

cell *in vivo* are maintained for the reasons of record advanced on pages 4-6 of the Office action mailed on January 16, 2003; however, the aspects of the previous enablement rejection directed to variants of the promoter sequence of the invention have been withdrawn.

The Examiner stated that applicant's arguments filed April 21, 2003 have been fully considered but they are not persuasive. The Examiner noted applicant's contentions that introduction and expression of recombinant expression constructs in living cells has been known to those skilled in the art for twenty years; that many techniques have been developed for introducing foreign DNA into mammalian cells; and that the claims are enabled to the extent of reading on transformation of living cells. The Examiner, however, maintained that methods of transforming cells *in vivo* are encompassed within the field of gene therapy, and that the art of gene therapy was unpredictable at the time the claimed invention was filed and has remained unpredictable thereafter.

In response, without conceding the correctness of the Examiner's position but solely to advance the prosecution of the subject application, the applicant has amended claims 15-25 to recite cells in cell culture, thereby making the Examiner's concerns moot. Accordingly, applicant's amended claims meet the enablement requirement of 35 U.S.C. 112, and this rejection should be withdrawn.

For the record, however, applicant point out that the preparation of recombinant expression constructs, inserting them into living cells, and expressing the constructs in living cells has been known to those skilled in the art for at least twenty (20) years prior to the filing of the subject application. For example, in

Applicant : Alan R. Tall  
Serial No.: 09/560,372  
Filed : April 28, 2000  
Page 10

1977, Wigler, M., et al., Cell 11: 223-232 (1977) described transformation of eucaryotic cells, specifically mammalian cells, with foreign DNA coding for a selectable phenotype. Over the years, a number of techniques have been developed for introducing DNA into mammalian cells, e.g. calcium phosphate coprecipitation, DEAE-dextran, microinjection, protoplast fusion, electroporation, lipofection, etc. Therefore, to the extent applicant's claims read on transformation of living cell, the claims are enabled. Furthermore, after making transformed mammalian cells, it is hardly difficult to insert such transformed cell back into the mammal. Indeed, numerous cancer researchers use xenografting to study development of tumors. Thus, applicant finds the Examiner's rejection unfounded in view of this large body of prior art showing *in vivo* transformation of cells.

**Rejection under 35 U.S.C. § 112, second paragraph**

On pages 5-6 of the August 28, 2003 Office Action, the Examiner rejected claims 1-2, 5-16, 18-25 and 50-51 under 35 U.S.C. § 112, second paragraph, as allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner alleged that claim 1 is indefinite as written because the nucleotide sequence set forth in SEQ ID NO:1 does not comprise nucleotides that have negative numbering. As such, the Examiner noted that it is not clear which nucleotide bases of SEQ ID NO:1 correlate to the sequence beginning at bp -469 and ending at bp +101 or to the sequence beginning at bp -101 and ending at bp -32. The Examiner did note that Figure 3, as described on page 7, provides the nucleotide sequence set forth in SEQ ID NO:1 in the context of an actual promoter sequence by depicting the regions of SEQ ID NO:1 that are upstream and downstream of the transcription initiation site. For example the 5' end of the sequence is

Applicant : Alan R. Tall  
Serial No.: 09/560,372  
Filed : April 28, 2000  
Page 11

position -928 and the 3' end of the sequence is +101; and a Sac I restriction site is positioned at -469. However, the Examiner noted that comparison of the sequences of Figure 3 and SEQ ID NO:1 suggests that a discrepancy exists with respect to position -469 (the SacI site), specifically in that the SacI site as shown in Figure 3 is not at position -469 but rather is at position -471, and also, in that the length of the 5' end of exon 1 as shown by the bolded sequence in figure 3 is longer than 101 bases suggesting that the sequence does not end at position +101 as discussed in the specification on pages 7-8. In light of the above, the Examiner suggested amending the claims to recite a correlation between the exact sequences in Figure 3 and SEQ ID NO:1 as embraced by the claim in steps b and c.

In response, applicant has amended claim 1 and claim 50 to more clearly recite applicant's invention. Applicant thanks the Examiner for pointing out the ambiguity in the claims. Applicant has amended claim 1 and 50 to use the numbering of SEQ ID NO. 1.

Initially, applicants notes that the sequence of SEQ ID NO. 1 corresponds to the sequence set forth in Figure 3 of the subject application. To assist in correlating the nucleotide numbering used in SEQ ID NO.1, which are now also used in amended claim 1, to the markings in the sequence of Figure 3, applicant has reproduced in **Exhibit A** hereto the sequence of SEQ ID NO. 1 and has marked thereon the location of the SacI site, the SP1 site and the TATAA box element from Figure 3.

The Examiner will note that directly to the right of the SacI site is nucleotide number 624 of SEQ ID NO. 1. Thus, the recitation in amended claim 1 of a nucleotide sequence beginning at bp 624 and ending at bp 1197 of SEQ ID NO: 1 is clear.

Applicant : Alan R. Tall  
Serial No.: 09/560,372  
Filed : April 28, 2000  
Page 12

The Examiner will also note that the segment of nucleotides in between the SP1 site and the TATAA box element begins with nucleotide number 1005 and ends with nucleotide number 1059 in SEQ ID NO. 1. Thus, the recitation in amended claim 1 of a nucleotide sequence beginning at bp 1005 and ending at bp 1059 of SEQ ID NO: 1 is clear.

To summarize, part a) of amended claim 1 recites the entire sequence set forth in SEQ ID NO. 1 and in Figure 3; part b) of amended claim 1 recites the 5' segment of SEQ ID NO. 1 that is downstream of the SacI site shown in Figure 3; and part c) of amended claim 1 recites the segment in between the Sp1 site and the TATAA box element shown in Figure 3. Furthermore, claim 1, as amended, is clearly supported by the subject application.

Accordingly, applicant's amended claims meet the definiteness requirement of 35 U.S.C. 112, and this rejection should be withdrawn.



In view of the above mentioned amendments and remarks, the Applicant requests that the Examiner reconsider and withdraw the rejections set forth in the August 28, 2003 Office Action.


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicant : Alan R. Tall  
Serial No.: 09/560,372  
Filed : April 28, 2000  
Page 13

No fee, other than the enclosed \$55.00 fee for a one-month extension of time, is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
 John P. White Reg. No. 28,678 Gary J. Gershik Reg. No. 39,992	 Date 12/12/03

  
John P. White  
Registration No. 28,678  
Gary J. Gershik  
Registration No. 39,992  
Attorneys for Applicant  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

Applicant : Alan R. Tall  
Serial No.: 09/560,372  
Filed : April 28, 2000  
Page 14

SEQ ID NO. 1

```
acctgagttt tggccagaat aaggtgacat ttagtttggt ggcttgatgg atgacttaaa 60
tatttagaca tatggtgtgt aggcctgcat tcctactctt gccttttttt ttgcccctcc 120
agtgttttgg gtagttttgc tcccctacag ccaaaggcaa acagataagt tggagggtctg 180
gagtggctac ataattttac acgactgcaa ttctctggct gcacttcaca aatgtaataca 240
aactaaatac aagtcctgtg tttttatcac agggagggtg atcaatataa tgaaattaaa 300
agggggctgg tccatattgt tctgtgtttt tgtttgtttg tttctttttt tgtttttgtg 360
gcctccttcc tctcaattta tgaagagaag cagtaagatg ttctctcgg gtcctctgag 420
ggacctgggg agctcaggct gggaatctcc aaggcagtag gtcgcctatc aaaaatcaaa 480
gtccaggttt gtggggggaa aacaaaagca gccattacc cagaggactg tccgccttcc 540
cctcacccca gcctaggcct ttgaaaggaa acaaaagaca agacaaaatg attggcgctcc 600
tgaggagat tcagcctaga gctctctctc cccaatccct ccctccggct gaggaaacta 660
      ^ SacI
acaaaggaaa aaaaaattgc ggaaagcagg atttagagga agcaaattcc actggtgccc 720
ttggctgccg ggaacgtgga ctagagagtc tgcggcgcag ccccgagccc agcgcttccc 780
gcgcgtctta ggccggcggg cccgggcggg ggaaggggac gcagaccgcg gaccctaaga 840
cacctgctgt accctccacc cccacccac ccacctcccc ccaactccct agatgtgtcg 900
tgggcggctg aacgtcgccc gtttaagggg cgggccccgg ctccacgtgc tttctgctga 960
gtgactgaac tacataaaca gaggccggga acggggcggg gaggaggag agcacaggct 1020
      SP1
ttgaccgata gtaacctctg cgctcggtgc agccgaatct ataaaaggaa ctagtcccgg 1080
caaaaacccc gtaattgcga gcgagagtga gtggggccgg gaccgcgaga gccgagccga 1140
cccttctctc ccgggctgcg gcagggcagg gcggggagct ccgcgcacca acagagc 1197
```